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ACC/AHA Clinical Data Standards
Preamble
The American College of Cardiology (ACC) and the Amer-
ican Heart Association (AHA) recognize the importance of
refining the lexicon used to describe the process and out-
comes of clinical care, whether in randomized trials, obser-
vational studies, registries, or quality-improvement initia-
tives. Broad professional agreement on a common vocabulary
with common definitions will facilitate cross-study compar-
isons or, when advantageous, combining of data across
studies and will improve the assessment of any project’s
generalizability to clinical practice. To further efforts aimed
at standardizing such a lexicon, the ACC and AHA have
undertaken to develop and publish clinical data standards,
sets of standardized data elements and corresponding defini-
tions that can be used in a variety of data collection efforts for
a range of cardiovascular conditions.
It is hoped that these clinical data standards will:
1. Improve cross-comparison of results and clinical out-
comes between different trials and registries.
2. Facilitate the development and conduct of future regis-
tries, at both hospital and national levels, by providing
a list of major variables, outcomes, and definitions.
3. Facilitate measurement for quality-improvement
programs.
4. Become the basis for a standardized charting process
with the anticipation that medical charting will progress
to an electronic format.
The ACC/AHA Task Force on Clinical Data Standards
makes every effort to avoid any actual or potential conflicts of
interest that might arise as a result of an outside relationship
or a personal interest of a member of the writing panel.
Specifically, all members of the writing panel are asked to
provide disclosure statements of all such relationships that
might be perceived as real or potential conflicts of interest.
These statements are reviewed by the parent task force,
reported orally to all members of the writing panel at the first
meeting, and updated as changes occur.
The ACC/AHA Task Force on Clinical Data Standards
selects cardiovascular conditions and procedures that would
benefit from the creation of a data standard set. Experts in the
subject are selected to examine/consider existing data stan-
dards and develop a comprehensive, yet not exhaustive, data
standard set. Users should understand that when they under-
take a data collection effort, only a subset may be needed, or
conversely, they may want to consider whether it may be
necessary to collect some elements not listed. For example, in
the setting of a randomized clinical trial of a new drug,
additional information would likely be required regarding
study procedures and drug therapies.
The ACC and AHA aim to standardize the language used
to describe cardiovascular diseases and procedures, enhance
consistency in cardiology, and increase opportunities for
sharing data across various data sources. The ultimate goal of
ACC/AHA clinical data standards is to contribute to the
infrastructure necessary for accomplishing the ACC/AHA’s
mission of fostering optimal cardiovascular care and disease
prevention.
The ACC and AHA support the goals of its members to
improve cardiovascular care and disease prevention through
professional education, promotion of research, development
of guidelines and standards for cardiovascular care, and the
fostering of policy that supports optimal patient outcomes.
The ACC and AHA recognize the importance of the use of
clinical data for patient management, in the assessment of
patient outcomes, and in research efforts focused on improv-
ing clinical treatment of patients.
As a component of this objective, the ACC/AHA clinical
data standards concentrate on the identification, definition,
and standardization of data that correspond to various clinical
topics in cardiology. The primary goal of clinical data
standards is to assist in the collection of data by providing an
initial platform of data elements and corresponding defini-
tions applicable to various disease conditions in cardiology.
These key elements and definitions are a compilation of
variables applicable in the measurement of patient clinical
management and outcomes and for research and epidemio-
logical assessments.
The Health Insurance Portability and Accountability Act
(HIPAA) privacy regulations, which went into effect in April
2003, have heightened all practitioners’ awareness of our
professional commitment to safeguard our patients’ privacy.
Our goal is to treat every patient’s health information with the
same respect and courtesy as their person. The HIPAA
privacy regulations (http://www.hhs.gov/ocr/combinedregtext.
pdf, page 31) specify which information elements are con-
sidered “protected health information.” These elements may
not be disclosed to third parties (including registries and
research studies) without the patient’s written permission, and
research studies that use protected health information must be
reviewed by an Institutional Review Board or a Privacy
Board.
We have included identifying information in all clinical
data standards to facilitate uniform collection of these ele-
ments when appropriate. For example, a longitudinal clinic
database may contain these elements, because access is
restricted to the patient’s caregivers. On the other hand,
registries may not contain protected health information unless
specific permission is granted by each patient. These fields
are indicated as protected health information (PHI) in the data
standards.
Our understanding of the importance of data element
standardization, derives from experience with clinical care,
clinical research, and quality-performance measurement. In
clinical care, caregivers communicate with each other
through a common vocabulary. The integrity of clinical
research depends in large part on firm adherence to prespeci-
fied procedures for patient enrollment and follow-up; these
procedures are guaranteed through careful attention to defi-
nitions enumerated in the study design and case report forms.
When data elements and definitions are standardized across
studies, comparison, pooled analysis, and meta-analysis are
facilitated, thus deepening our understanding of individual
clinical trials.
The recent development of quality-performance measure-
ment initiatives, particularly those for which comparison of
providers is an implicit or explicit aim, has further raised
awareness among the professional community about the
importance of data standards. For the first time, a wide
audience, including nonmedical professionals such as payers,
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regulators, and consumers, may draw conclusions about care
and outcomes. For comparison of care patterns and outcomes
to be fair, the data elements that compose the descriptions of
these patterns and outcomes of care must be clearly defined,
consistently used, and properly interpreted by a broader
audience than ever before.
Martha J. Radford, MD, FACC, FAHA
Chair, ACC/AHA Task Force on Clinical Data Standards
I. Introduction
Atrial fibrillation (AF) is the most common arrhythmia
encountered in clinical practice. Prevalence of AF increases
with age, reaching as high as 9% in octogenarians (1–4). New
pharmacological and nonpharmacological treatments, as well
as results from some large clinical trials (5–7), have increased
interest in the management of AF. To address this increased
need and interest, the American College of Cardiology
(ACC), the American Heart Association (AHA), and the
European Society of Cardiology (ESC) jointly released the
ACC/AHA/ESC Guidelines for the Management of Patients
With Atrial Fibrillation (8). The ACC and AHA are following
this effort with the ACC/AHA Key Data Elements and
Definitions for Measuring the Clinical Management and
Outcomes of Patients With Atrial Fibrillation. AF is one of
several conditions identified for development of clinical data
standards by the ACC/AHA Task Force on Clinical Data
Standards and is preceded by clinical data standards on acute
coronary syndrome.
A. Purpose
The ACC/AHA Atrial Fibrillation Data Standards Writing
Committee proceeded to develop data elements and defini-
tions with the goal that they may be useful in a variety of
circumstances:
● Clinical programs, where many providers and health plans
work together to achieve specific goals for the care of
patients with AF. Data standards will assist in the organi-
zation and design of electronic medical information initia-
tives, such as electronic medical records, pharmacy and
other clinical databases, or computerized decision support.
● Clinical research, including prospective registries and
randomized controlled trials (RCTs). Meta-analyses of
RCTs would be particularly strengthened by the use of
standardized data for key variables.
● Quality-performance measurement initiatives. Data stan-
dards will especially facilitate interpretation for nonmedi-
cal users, such as payers, regulators, and consumers.
These data standards were designed to facilitate the above
initiatives. Because they were developed to support many
varied uses, they were not designed to provide an operational
format for any one specific use. Thus, the definitions are often
stated in a more general fashion than will be appropriate for
certain purposes. More specific operational definitions likely
will be used for actual data collection, with these data
standards providing a uniform guide for their development. In
addition, because the data standards were developed for
potential application in varied environments, all elements are
not expected to pertain to each application.
II. Methodology
A. Writing Committee Composition
The ACC/AHA Writing Committee to Develop Clinical Data
Standards for Atrial Fibrillation included a group of 13
physicians who are active in clinical programs, clinical
research, and/or quality-performance measurement initiatives
in AF. To improve generalization to a broad population, the
committee included membership from the United States,
France, and Canada. To ensure consistency within the topic
of AF, the committee included three members from the
ACC/AHA/ESC Committee to Develop Guidelines for the
Management of Patients With Atrial Fibrillation. To enhance
uniformity among different data standards efforts, the com-
mittee included one member from the ACC/AHA Task Force
on Clinical Data Standards.
B. Review of Literature and Existing Data
Definitions
The AF data standards are intended to provide data elements
that parallel and complement other ACC and AHA standards,
specifically guidelines. The ACC/AHA/ESC Guidelines for
the Management of Patients With Atrial Fibrillation (8)
served as the primary evidence-based document that was
referenced in the development of data elements and defini-
tions for this statement. The writing committee gathered as
many additional candidate data elements and definitions as
possible from large clinical trials, national quality-perfor-
mance measurement initiatives, relevant guidelines, and other
national, international, and local cardiovascular data collec-
tion efforts. Examples of these data sources include the Atrial
Fibrillation Follow-up Investigation of Rhythm Management
(AFFIRM) (7,9), the AnTicoagulation and Risk factors In
Atrial fibrillation (ATRIA) Study (4), the ALFA Study
(Etude en Activité Liberale sur le Fibrillation Auriculaire)
(10), the Canadian Trial of Atrial Fibrillation (11,12), and the
Canadian Registry of Atrial Fibrillation (CARAF) (13).
C. Prioritizing Data Elements
Once the writing committee reviewed the relevant literature
and additional resources, a comprehensive list of potential
items was created with the understanding that the final set
would be limited to those elements most likely to be needed
in data collection efforts. The initial list of data elements was
graded according to priority as “high,” “medium,” or “low.”
All of the data elements with an average “high” score and a
majority of those with an average “medium” score were
included in the final set. The remaining elements are not
included at this time but may be added and defined in the
future.
The subsequent process of writing and revising data
element definitions included prioritizing, adding, and remov-
ing elements for the purpose of defining the elements in a
manner that facilitates consistent data collection.
D. Defining Data Elements
Members of the writing committee were assigned to one of
four working groups, each of which was responsible for
drafting definitions for a subset of data elements deemed to
have priority for the first publication of the AF data standards.
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Each writer received a template to assist in drafting the
definitions and to provide for a structured format across
authors. Writers were encouraged to compose definitions that
were broad enough to be applicable in a variety of data
collection settings (e.g., inpatient versus outpatient) but
specific enough that the data elements could be uniformly
interpreted.
To ensure consistency across ACC/AHA clinical data
standards and clinical guidelines, previously published defi-
nitions were used verbatim whenever appropriate. Further-
more, data element definitions were linked to pre-existing
definitions.
E. Writing Considerations for Use
The writing committee determined three major settings in which
these data elements may be particularly useful: clinical care,
clinical research, and quality-performance measurement.
F. Consensus Development
The ACC/AHA data standards are consensus, team-written
documents that are based on judgments of experts in the field
of cardiology. This writing committee met several times, both
in person and through conference calls, over the course of 18
months to define and refine the data elements and definitions.
Consensus was met through meetings, conference calls, and
e-mail communications.
G. Peer Review, Public Comment, and Board
Approval
The set of AF data elements was reviewed by 6 official
reviewers nominated by the ACC, AHA, and the ACC/AHA
Task Force on Clinical Data Standards and 10 individual
content reviewers (see Appendix A for names and affilia-
tions). To increase its applicability further, the document was
posted on the ACC World Wide Web site for a 30-day public
comment period between July 30 and August 30, 2003.
Response forms were received from 63 individuals, repre-
senting 15 countries, including the United States. The docu-
ment was approved for publication by the governing bodies
of the ACC and the AHA. The document has been formally
endorsed by the Mediterranean Society of Pacing and Elec-
trophysiology. To determine whether a revision is necessary,
these clinical data standards will be reviewed one year after
publication and yearly thereafter by the ACC/AHA Task
Force on Clinical Data Standards.
H. Document Format
This document is divided into three sections, outlined as
follows:
1. Introduction: A description of the methodology for
developing the AF clinical data standards and intended
goals for their use.
2. Data Elements and Definitions: A listing of key data
elements and definitions.
3. Reference Guide: A multipurpose resource that maps
common data fields between AF data elements and
other national/regional data registries and links
AF data elements to relevant ACC/AHA guidelines
(available online at www.acc.org/clinical/data_standards/
AF/pdf/AF_refguide.pdf).
III. General Considerations of the AF Clinical
Data Standards
A. Patient-Oriented Format
Given that AF is a chronic condition, the individual patient is
the foundation of this data element set. This focus contrasts
with other comparable efforts in which the field of interest
may be a procedure (e.g., cardiac catheterization) or an event
(e.g., acute coronary syndrome). Thus, the format of these
data elements was designed to follow multiple events over
time for each individual patient.
B. Balance Between Focus and Comprehensiveness
The writing committee focused on commonly collected data
elements that were thought to be most useful for the broadest
set of applications. These data standards are not intended to
be a comprehensive data element catalog, encompassing
every possible data need or use. The writing committee
realizes that individual users likely will supplement these
elements to suit their individual needs. Conversely, other
users will select only a few data elements to collect.
C. Dates
The committee recognizes the critical importance of obtain-
ing dates for most data elements in order to understand the
clinical course, therapy, and outcomes of AF for the individ-
ual patient and across populations. The exact date (month,
day, and year) for all elements and dates of events for
prospective data elements should be obtained whenever
possible. Because the ability to obtain precise dates of prior
events is limited, best estimate of dates should be obtained
(e.g., month/year), with emphasis placed on the most current
events. The operational format of date collection will vary
depending on particular use.
D. Varied Clinical Presentations
These data elements are intended to encompass the full range
of patients with AF, including acute and chronic presenta-
tions, inpatient and outpatient settings, and scheduled and
unscheduled medical care encounters.
E. Balance Between Primary and Summary Data
Elements
These data elements consist of both individual data elements
(for example, age and left atrial size) and summary elements
(for example, New York Heart Association [NYHA] class for
heart failure and primary cardiac diagnosis). In general, the
committee included summary elements only to supplement
primary data elements.
F. Atrial Fibrillation-Specific Elements
When possible, the committee chose data element names and
definitions common to other ACC/AHA clinical data stan-
dard efforts. However, some elements were designed to
specifically meet the needs of patients with AF. The commit-
tee wanted to highlight a subset of these AF-specific elements
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that were particularly noteworthy. These elements appear in
bold print in the “Element” column. They are:
Section II.A. Retrospective Data
Patient Category:
• Qualifying cardiac rhythm
• Predominant cardiac diagnosis
• Atrial fibrillation due to transient or revers-
ible cause
Prior AF:
• Previously used therapeutic strategies
• Frequency of prior symptomatic episodes
• Duration of prior symptomatic episodes
Section II.B. Prospective Data
General:
• Primary reason for encounter
• Patient classification of type of AF episodes
• Current management strategy
Quality of Life:
• Symptoms with prior episodes of AF
Cardioversion:
• Success of cardioversion attempt
• Pattern of recurrence
• Complications of conversion
Resource Utilization:
• Primary reason for admission
• Procedures performed
• Specialty of principal provider
G. Quality of Life
Considerations of quality of life are particularly important in
the management of AF. The currently available general health
status measures, such as EuroQOL (www.euroqol.org), the
SF-36 (14), or the SF-12 (15), are valuable in the breadth of
domains that they measure and in their use for comparison
across disease states. However, valid and reliable measures
focused on the specific health burdens of AF are needed to
supplement general health status measures. These focused
measures may quantify health status effects of the arrhythmia
itself, such as the AF Severity Scale and AF Symptom
Burden Checklist used by the Canadian Registry of Atrial
Fibrillation (16); of complications, such as stroke (National
Institutes of Health Stroke Scale (17)); or of therapy, such as
inconvenience and lifestyle changes associated with chronic
warfarin therapy (18). At this point, no single approach to
measurement of health status of patients with AF can be
recommended.
H. Atrial Flutter and Other Atrial Tachycardias
Although many elements and definitions within this docu-
ment will apply to patients with atrial flutter and other atrial
tachycardias, the identification and definition of the unique
features of these rhythms are not within the scope of this
document.
Staff
American College of Cardiology Foundation
Christine W. McEntee, Chief Executive Officer
Frances F. Fiocchi, MPH, Senior Specialist, Research and
Innovation
Susan L. Morrisson, Associate Specialist, Clinical Policy and
Documents
American Heart Association
M. Cass Wheeler, Chief Executive Officer
Rose Marie Robertson, MD, FACC, FAHA, Chief Science
Officer
Fernando Costa, MD, FAHA, Staff Scientist
IV. Atrial Fibrillation Clinical Data Elements
and Definitions
Note, boldfaced type in Tables 1 and 2 indicates elements of
particular relevance to atrial fibrillation (AF).
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TABLE 1. Retrospective and Concurrent Data (Collected at or Near the Time of Study Initiation)*
ELEMENT DEFINITION
Patient Demographics
Registry or study identifier Unique encrypted numeric identifier (unrelated to subject’s personal identifying information) to enhance comparisons
across studies while protecting patient privacy
Date of study entry Date of initiation of collection of information for study purposes
Date of birth Patient date of birth (day, month, and year of patient’s birth)
Gender Indicate the patient’s gender at birth. Choose one of the following:
• Male
• Female
Hispanic ethnicity Is this patient Spanish, Hispanic, or Latino? Choose one of the following:
• Yes
• No
Race Patient’s race as determined by the patient/family:
• American Indian or Alaska Native
• Asian
• Black or African American
• Native Hawaiian or other Pacific Islander
• White
• Other
• Unknown
Insurance payer Indicate the patient’s primary insurance payer for this admission. Choose one of the following:
• Government: Refers to patients who are covered by government-reimbursed care. In the U.S., this includes
Medicare, Medicaid (including all state or federal Medicaid-type programs), Champus, and the Veteran’s
Administration health plan.
• Commercial: Refers to all indemnity (fee-for-service) carriers and preferred provider organizations (PPOs).
• HMO: Refers to a health maintenance organization characterized by coverage that provides healthcare services
for members on a prepaid basis.
• None: Refers to individuals with no or limited health insurance; thus, the individual is the payer regardless of
ability to pay. Only mark “None” when “self” or “none” is denoted as the first insurance in the medical record.
• Non-U.S. Insurance: Refers to individuals who reside in and have health insurance in another country.
Government payer type If the patient’s primary insurance payer for this encounter is “Government,” choose the type of government insurance:
• Medicare
• Medicaid
• Other
Education Indicate the highest degree the patient has received. Categories include (recommend listing years of schooling if
degrees do not apply to a specific population):
• Less than high school graduate (fewer than 12 years)
• High school graduate or equivalent (12 years)
• Some college (more than 12 but fewer than 16 years)
• Bachelor’s degree (16 years)
• Master’s degree or higher degree (more than 16 years)
Patient Category
Qualifying cardiac rhythm Rhythm recorded that qualified the person for the study:
• First-detected AF
• Paroxysmal AF: AF is self-terminating within 7 days of recognized onset
• Persistent AF: AF is not self-terminating within 7 days or is terminated electrically or pharmacologically
• Permanent AF: Cardioversion failed or not attempted
Predominant cardiac diagnosis Exclusive categories include:
• Mitral stenosis, with or without regurgitation
• Coronary artery disease, with or without left ventricular dysfunction (prior documented myocardial infarction,
angina, coronary revascularization, or stenosis on angiography greater than or equal to 50%)
• Other structural heart disease, including nonischemic left ventricular systolic dysfunction (left ventricular ejection
fraction less than 40% or fractional shortening less than 25%), moderate or severe valvular heart disease,
asymmetrical left ventricular hypertrophy, and congenital heart disease. Exclude concentric left ventricular
hypertrophy.
• Hypertension, with or without left ventricular hypertrophy
• No underlying structural or functional heart disease or hypertension
Atrial fibrillation due to transient
or reversible cause
Indicate whether the qualifying AF is due to a transient or reversible cause. Indicate all that apply:
• Postoperative from cardiac surgery
• Postoperative from noncardiac thoracic surgery
• Postoperative from noncardic, nonthoracic surgery
*Boldfaced type indicates elements of particular relevance to atrial fibrillation (AF).
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TABLE 1. Continued
ELEMENT DEFINITION
• Pericarditis
• Lung disease
• Hyperthyroidism
• Other, specify
Prior Atrial Fibrillation
Previously used therapeutic
strategies
Indicate the types of therapeutic strategies that have been employed previously. Indicate all that apply. (Note: One
therapy may apply to more than one category, e.g., amiodarone may be used for rate and rhythm control.)
Rate Control:
• Pharmacological
• Nonpharmacological
• Hybrid*
• None
Rhythm Control:
• Pharmacological
• Nonpharmacological
• Hybrid*
• None
*Hybrid is defined as concurrent use of:
• Pharmacological and nonpharmacological therapies or
• 2 or more nonpharmacological therapies
Frequency of prior symptomatic
episodes
Patient estimate of average interval between symptomatic episodes in days
Duration of prior symptomatic
episodes
Patient estimate of duration of each of longest, shortest, and usual symptomatic episodes:
• Less than 48 hours
• 48 hours to 7 days
• 7 days to 3 months
• Longer than 3 months
If more specific short-term intervals are desired, recommend dividing the first category (less than 48 hours) into the
following: less than 5 minutes, 5 minutes to less than 6 hours, 6 hours to less than 48 hours.
Successful prior pharmacological
cardioversion
List all generic drug names previously used that resulted in the absence of AF or atrial flutter.
Unsuccessful prior pharmacological
cardioversion attempted
List all generic drug names previously used that did not result in the absence of AF or atrial flutter.
Successful prior transthoracic
electrical cardioversion
Number of previous transthoracic electrical cardioversion sessions attempted that resulted in the absence of AF or
atrial flutter. A session may include multiple successive shocks.
Unsuccessful prior transthoracic
electrical cardioversion attempted
Number of previous transthoracic electrical cardioversion sessions attempted that did not result in the absence of AF
or atrial flutter. A session may include multiple successive shocks.
Successful prior transvenous
electrical cardioversion
Number of previous transvenous electrical cardioversion sessions attempted that resulted in the absence of AF or
atrial flutter. A session may include multiple successive shocks.
Unsuccessful prior transvenous
electrical cardioversion attempted
Number of previous transvenous electrical cardioversion sessions attempted that did not result in the absence of AF
or atrial flutter. A session may include multiple successive shocks.
History of ablation for
supraventricular arrhythmia
Documented history of ablation for supraventricular arrhythmia.
Indications (may have more than one):
• Supraventricular tachycardia (e.g., atrioventricular node re-entry tachycardia, atrioventricular re-entry
tachycardia)
• AF
• Atrial flutter
• Atrial tachycardia
• Other, specify
For AF/atrial flutter, indicate approach taken:
• Focal (specify site)
• Cavotricuspid isthmus
• Other linear sites, specify
• AV node ablation plus permanent pacemaker
Indicate energy source:
• Radiofrequency
• Cryoablation
• Ultrasound
• Laser
• Other, specify
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TABLE 1. Continued
ELEMENT DEFINITION
Thromboembolic History
History of ischemic stroke Documented history of stroke or cerebrovascular accident with acute loss of neurological function caused by an
ischemic or hemorrhagic event with residual symptoms at least 24 hours after onset.
List most likely etiology:
• Larger-artery disease (e.g., carotid)
• Small-artery disease (lacunar)
• Embolism
• Other, specify
• Not specified
Indicate whether confirmed by CT, MRI scan, or cerebral angiography.
Residual deficit from prior stroke Assessed via current level of functioning. Categories include:
• Complete/near-complete recovery (able to return to prestroke level of function)
• Mild to moderate deficit (deficits present, but patient can perform activities of daily living, such as dressing and
feeding, with no or little assistance)
• Severe deficit (required assistance to complete activities of daily living)
History of transient ischemic attack Documented history of transient ischemic attack (TIA) consisting of acute loss of neurological function caused by an
ischemic event with resolution of symptoms by 24 hours after onset.
History of systemic peripheral
embolism
Documented history of abrupt vascular insufficiency associated with clinical and radiological or pathological evidence
of arterial occlusion in a vascular bed other than the cerebrovascular system in the absence of other likely
mechanisms (e.g., atherosclerosis). Indicate site.
History of carotid artery disease History of carotid artery disease with 50% or more stenosis. Indicate all modalities of assessment:
• Ultrasound
• Magnetic resonance angiography
• Angiography
Hemorrhagic History
History of intracranial hemorrhage History of any prior bleeding into or around the brain. Categories include:
• Hemorrhagic conversion of a primary ischemic stroke
• Subarachnoid hemorrhage
• Intracerebral hemorrhage
• Other (including subdural and epidural hematomas)
• Unknown
Indicate whether documented by CT or MRI
Residual deficit from prior
intracranial hemorrhage
Assessed via current level of functioning. Categories include:
• Complete/near-complete recovery (able to return to prestroke level of function)
• Mild to moderate deficit (deficits present, but patient can perform activities of daily living, such as dressing and
feeding, with no or little assistance)
• Severe deficit (requires assistance to complete activities of daily living)
History of other hemorrhage History of bleeding is defined as either major or minor according to the following criteria:
• Major: Leading to transfusion of at least 2 units of whole blood or erythrocytes, requiring hospitalization or
surgery, resulting in permanent disability, or involving a critical anatomic site (retroperitoneal, pericardial,
intraspinal, intracranial, atraumatic intra-articular, or intra-ocular bleeding associated with abrupt deterioration of
visual acuity).
• Clinically overt (but not major)
• Occult (e.g., asymptomatic guaiac-positive stool)
Include amount of hemoglobin drop and the time interval if data available.
Other Cardiovascular History
History of hypertension Indicate whether the patient has hypertension as documented by:
• History of hypertension diagnosed and treated with medication, diet, and/or exercise
• Blood pressure greater than or equal to 140 mm Hg systolic or 90 mm Hg diastolic on at least 2 occasions
• Currently undergoing antihypertensive pharmacological therapy
More than one of the above may apply. The year of onset (first diagnosis) may be helpful.
History of heart failure Physician documentation or report of any of the following symptoms of heart failure before this care encounter,
described as dyspnea, fluid retention, or low cardiac output secondary to cardiac dysfunction; or the description of
rales, jugular venous distension, or pulmonary edema. A previous hospital admission with principal diagnosis of heart
failure is considered evidence of heart failure history.
History of valvular heart disease Documented history of moderate or severe stenosis or regurgitation. Indicate stenosis or regurgitation for each valve
involved. Date of onset (first diagnosis) may be helpful.
History of valve intervention Indicate each valve repair, valvuloplasty, or valve replacement in patient history. For valve replacement, indicate
location and type.
History of myocardial infarction (MI) Previous MI before this encounter as determined by the following (indicate all that apply):
• Hospital admission for acute MI
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• Electrocardiogram (ECG) report indicating previous (old) or acute MI
• Increase in biochemical marker (e.g., creatine kinase or troponin) consistent with MI
• Patient reports history of acute MI or heart attack
Date of the first and the most recent episodes may be helpful.
History of other coronary artery
disease
Indicate whether there is a documented history of any of the following:
• Prior coronary artery bypass surgery (CABG)
• Prior percutaneous coronary intervention (PCI)
• Angiographically documented coronary artery stenosis greater than or equal to 50%
• Positive stress test; specify imaging modality if performed
• Angina pectoris
History of hypertrophic
cardiomyopathy
Echocardiographically established hypertrophic cardiomyopathy. Specify type:
• Obstructive
• Nonobstructive, nonhypertensive
Does not include hypertensive cardiomyopathy (concentric hypertrophy).
History of cardiomyopathy Left ventricular systolic dysfunction with an estimated ejection fraction less than 0.40.
History of congenital heart disease Cardiac anomaly present from birth or congenital abnormality on echocardiography. Specify diagnosis and any prior
repair.
History of ventricular arrhythmias Ventricular tachycardia or ventricular fibrillation requiring cardioversion and/or medication (intravenous or oral) with
antiarrhythmic drugs.
History of sinus bradycardia/sick
sinus syndrome
Symptoms due to sinus node dysfunction and manifested by the following (indicate all that apply):
• Sinus bradycardia: Sinus rate 40 to 50 bpm with normal P-wave axis and PR interval
• Severe sinus bradycardia: Sinus rate less than 40 bpm with normal P-wave axis and PR interval
• Sinus arrest: Sudden absence of sinus activity
• Sinoatrial exit block: Loss of sinus activity at an interval fixed to that of the basic P-P interval
• Tachycardia-bradycardia syndrome: Paroxysmal tachycardias followed by bradycardia upon termination
History of atrioventricular (AV) block Highest degree of block in past history:
• 1st Degree: P-R interval greater than 200 ms
• 2nd Degree:
Mobitz I (Wenckebach): gradual PR prolongation until AV block
Mobitz II: fixed PR interval until AV block
Advanced AV block (e.g., 2:1, 3:1)
• 3rd Degree (complete heart block): independent atrial and ventricular activity with an atrial rate faster than the
ventricular rate
History of supraventricular
tachycardia
Indicate any documented history of:
• Atrial tachycardias
• AV nodal re-entrant tachycardias
• Orthodromic re-entrant tachycardias utilizing a concealed accessory bypass tract
• Other supraventricular tachycardias, including undifferentiated re-entrant tachycardias; specify
History of ablation for other than AF
or atrial flutter
Specify indication, which may include:
• Wolff-Parkinson-White syndrome (manifest accessory AV connection)
• AV nodal re-entrant tachycardias
• Concealed accessory bypass tracts
• Atrial tachycardias
• Ventricular tachycardia
History of pacemaker insertion Indicate whether the patient has or has had a pacemaker inserted. If yes:
Specify type:
• Single chamber (atrial)
• Single chamber (ventricular)
• Dual chamber (both atrial and ventricular, but not biventricular)
• Biventricular of any type
Specify indication (all that apply):
• Sinus node dysfunction
• AV block
• Congestive heart failure
• Atrial fibrillation
Specify if capable of:
• Burst pacing
• Antitachycardia pacing
History of intracardiac defibrillator
insertion
Indicate whether the patient has or has had an intracardiac defibrillator inserted. If yes:
Specify type:
• Single-chamber pacing and shock therapies; specify chamber
• Dual-chamber pacing and shock therapies
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• Atrial pacing with ventricular pacing and shock therapies
• Ventricular shock and biventricular pacing therapies
Specify indication:
• Atrial fibrillation
• Secondary prevention of cardiac arrest
• Primary prevention of cardiac arrest. High risk for ventricular tachycardia (e.g., ischemic heart disease,
hypertrophic cardiomyopathy, Brugada syndrome, long-QT syndrome, arrhythmogenic right ventricular
cardiomyopathy)
• Syncope with inducible ventricular tachycardia
• Unexplained syncope
Specify if capability exists:
• Burst pacing
• Antitachycardia pacing
• Cardioversion
Other Medical History
History of diabetes mellitus History of diabetes, regardless of duration of disease, need for antidiabetic agents, or a fasting blood sugar greater
than or equal to 7 mmol/l or 126 mg/dl. The year of onset (first diagnosis) may be helpful.
Diabetes control history Method of diabetic control at time of encounter. Choose one of the following:
• None: No treatment for diabetes
• Diet: Diet treatment
• Oral: Oral agent treatment
• Insulin: Insulin treatment
• Insulin and oral: Insulin and oral agent treatment
History of chronic lung disease Documented history of chronic lung disease (e.g., chronic obstructive pulmonary disease, chronic bronchitis) or
currently being chronically treated with inhaled or oral pharmacological therapy (e.g., beta-adrenergic agonist,
anti-inflammatory agent, leukotriene receptor antagonist, or steroid) for the indication of lung disease. Date of onset
(first diagnosis) may be helpful.
History of thyroid disease History of hyperthyroidism or hypothyroidism. Indicate history of prior radioactive iodine treatment or prior medical
treatment for hyperthyroidism.
History of chronic kidney disease Stages are determined by measured or estimated glomerular filtration rate:
• None: Greater than or equal to 90 mL/min/1.73 m2 without kidney damage (e.g., proteinuria)
• Stage I: Greater than or equal to 90 mL/min/1.73 m2 with kidney damage (e.g., proteinuria)
• Stage II: 60 to 89 mL/min/1.73 m2
• Stage III: 30 to 59 mL/min/1.73 m2
• Stage IV: 15 to 29 mL/min/1.73 m2
• Stage V: Less than 15 mL/min/1.73 m2 or on maintenance dialysis
History of chronic liver disease Documented cirrhosis or chronic liver disease
Habits/Substance Abuse
History of alcohol
consumption/dependency
Alcohol consumption history:
• None
• One or fewer alcoholic drinks per week
• 2 to 7 alcoholic drinks per week
• 8 to 14 alcoholic drinks per week
• 15 or more alcoholic drinks per week
Alcohol dependency history:
• Documented alcohol dependence
• Medical sequelae of alcohol consumption (alcoholic hepatitis, cirrhosis, alcohol neuropathy,
Wernicke-Korsakoff syndrome)
• Treatment for alcohol dependency
For dependent consumers of alcohol, note treatment for dependency, cessation of use, or continued use.
History of smoking History confirming cigarette smoking in the past. Choose from the following categories:
• Current: Smoking cigarettes within 1 month of this encounter
• Recent: Stopped smoking cigarettes between 1 month and 1 year before this encounter
• Former: Stopped smoking cigarettes more than 1 year before this encounter
• Never: Never smoked cigarettes
For current or former smokers, total pack-years may be useful.
History of illicit drug use Documented history of current, recent, or remote abuse of any controlled substance. Indicate substance.
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Past Medications
Past antiarrhythmic
drugs and
rate-control agents
List generic names of all prior medications for rate and rhythm control. For each antiarrhythmic and rate-control medication used in
the past (above), indicate the primary reason for discontinuation:
• Ineffective
• Not tolerated, specify
• Other, specify
Past antithrombotic
medications
List generic names for all anticoagulation and antiplatelet medications (including aspirin and clopidogrel) used in the past. For each
antithrombotic medication used in past (above), indicate the primary reason for discontinuation:
• Ineffective
• Not tolerated, specify
• Other, specify
Past contraindication
to antithrombotic
therapy
Has patient been considered for antithrombotic therapy in the past but not treated due to a contraindication? If yes, list
contraindication.
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General
Type of encounter Type of encounter in healthcare facility:
• Emergency admission for AF
• Emergency admission for other cardiovascular problem
• Emergency admission for noncardiovascular problem (e.g., pneumonia)
• Planned admission for AF
• Planned admission for cardiovascular disease
• Planned admission for noncardiovascular disease
• Regularly scheduled outpatient visit
• Emergency room visit, not admitted
• Other outpatient visit
It may be useful to collect more specific information.
Primary reason for encounter Primary symptom or condition that prompted patient to seek medical attention:
• AF related
• Other cardiac-related reason
• Not cardiac related
Patient classification of type of AF
episodes
Classify patient based on the episodes of AF within the past 12 months:
• First Detected: Patient with a first-detected episode lasting fewer than 6 months
• Paroxysmal: Patient with history of 2 or more episodes of paroxysmal AF only
• Persistent: Patient with history of 2 or more episodes of persistent AF only
• Mixed Paroxysmal/Persistent: Patient with history of 2 or more episodes of AF of either paroxysmal
or persistent type
• Permanent: Patient with history of 2 or more episodes of AF with at least 1 episode of permanent
AF, or a first-detected episode lasting more than 6 months for which no attempt or further attempt
to restore sinus rhythm is planned
(See “Qualifying Rhythm” for definitions of episode classification.)
Current management strategy Indicate the types of strategies that are currently being employed. Indicate all that apply:
Rate Control:
• Pharmacological
• Nonpharmacological
• Hybrid*
Rhythm Control:
• Pharmacological
• Nonpharmacological
• Hybrid*
*Hybrid is defined as concurrent use of:
• Pharmacological and nonpharmacological therapies or
• Two or more nonpharmacological therapies.
Medications on Encounter
Antiarrhythmic drugs and rate-control
agents
List generic names of all antiarrhythmic and rate-control medications (including beta-blockers,
calcium-channel blockers, and digoxin) that are currently prescribed to patient. Indicate daily dose.
Antithrombotic agents List generic names for all antithrombotic and antiplatelet medications (including aspirin and clopidogrel)
that are currently prescribed to patient. Indicate daily dose.
Angiotensin-converting enzyme inhibitors List generic names for all angiotensin-converting enzyme inhibitors that are currently prescribed to patient.
Angiotensin receptor blockers List generic names for all angiotensin receptor blockers that are currently prescribed to patient.
Other cardiac medications List generic names for all other cardiac medications that are currently prescribed to patient.
Thyroid replacement Indicate whether patient is currently receiving thyroxine and/or T3.
Antidiabetic therapy Patient has current prescription for antidiabetic medication. Indicate type:
• Oral agent
• Insulin
• Both oral agent and insulin
Nonsteroidal anti-inflammatory drugs
(NSAIDs), not including aspirin or
cyclooxygenase (Cox)-2 inhibitors
List NSAIDs taken on average more than once per week. (Note: This category does not include aspirin,
acetaminophen, or Cox-2 inhibitors.)
Cox-2 inhibitor List Cox-2 inhibitors taken on average more than once per week.
Beta-agonists List inhaled and oral beta-2-adrenergic agonists taken on average more than once per week.
Physical Examination
Heart rate Heart rate (beats per minute) recorded closest to the time of presentation to the healthcare facility and/or on discharge
(for inpatient). Heart rate may be ascertained from ECG tracing or from record of physical examination.
*Note: Each element may be collected multiple times during clinical follow-up.
†Boldfaced type indicates elements of particular relevance to atrial fibrillation (AF).
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Systolic and diastolic blood pressure Systolic and diastolic blood pressure (mm Hg) recorded closest to the time of presentation to the
healthcare facility. Patient position (supine, sitting, other) should be noted.
Height Patient’s height in centimeters or inches (list units)
Weight Patient’s weight in kilograms or pounds (list units). Body mass index can be calculated from height and
weight.
Physical signs and symptoms of congestive
heart failure
Indicate whether patient meets criteria for congestive heart failure as defined by the Framingham Heart
Study (19). A diagnosis of heart failure requires that 2 major criteria are present or that 1 major and 2
minor criteria are present concurrently.
Major Criteria include:
• Acute pulmonary edema
• Cardiomegaly
• Increased venous pressure
• Neck vein distension
• Positive hepatojugular reflex
• Inspiratory rales
• S3 gallop
Minor Criteria include:
• Dyspnea on exertion
• Extremity edema
• Hepatomegaly
• Night cough
• Pleural effusion
• Tachycardia (more than 120 beats per minute)
Pregnancy Indicate whether the patient is pregnant.
Laboratory Tests (include local reference ranges)
Thyroid function tests • Serum thyroid-stimulating hormone level (U/mL–micro units per milliliter)
• Free T4 (local laboratory units)
• Total T3 (local laboratory units)
Serum creatinine Serum creatinine level (mg/dl or mmol/l)
Liver function/ assessment • Total bilirubin (g/dl)
• Alkaline phosphatase (IU/dl)
• Aspartate transaminase (AST) (U/dl)
• Alanine transaminase (ALT) (U/dl)
• Serum albumin (g/dl)
Potassium Serum potassium (mg/dl or mmol/l)
Magnesium Serum magnesium (mg/dl or mmol/l)
Hemoglobin Serum hemoglobin (mg/dl)
International Normalized Ratio (INR) Measured INR for assessment of anticoagulation status/prothrombin time
Goal INR Indicate the listed goal INR for the patient
• 2.5 to 3.5
• 2.0 to 3.0
• Other (specify goal INR range and reason)
Partial thromboplastin time (PTT) Indicate whether activators used (aPTT) or not (PTT). Measured in seconds.
Electrocardiography
Rhythm The categories of rhythm are:
• Sinus rhythm
• Atrial fibrillation
• Atrial flutter
• Paced
• Other rhythm (e.g., ventricular tachycardia, supraventricular tachycardia)
Heart rate on ECG Heart rate as measured on ECG. Recommended measurement is over at least 6 seconds.
Previous MI Indicate whether pathological Q waves are present on ECG.
Left ventricular hypertrophy Specify criteria. The following criteria have been validated prospectively in clinical studies:
• Sokolow-Lyon Voltage: S in V1R V5 or V6 greater than 38 mm (does not require gender or age
adjustment)
• Cornell Voltage: R avLS V3 greater than 20 mm in females or 28 mm in males
• Cornell Product: Cornell voltage times the QRS duration greater than 2440 (in females, 6 mm is
added to their Cornell voltage)
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Complete bundle-branch block Specify whether any of the following are present, defined as QRS more than 120 milliseconds:
• Right bundle-branch block
• Left bundle-branch block
• Nonspecific intraventricular conduction delay
Pre-excitation Indicate whether characteristic delta wave is present.
Atrial abnormality Indicate whether left, right, or biatrial abnormality is present.
U-waves Indicate whether U-waves are present.
Corrected QT (QTc) interval QTc interval measured from the ECG
Echocardiography
Echocardiographic modality Transthoracic or transesophageal
Left atrial size—M-mode on
echocardiography
Left atrial size, using the “leading edge to leading edge” method, in centimeters, measured from M-mode
in the parasternal long-axis view at end-ventricular systole.
Left atrial volume on echocardiography On two-dimensional imaging, using the left atrial areas traced in the four- and two-chamber views as
calculated by the standardized methods (e.g., Simpson’s method of disks) (20).
Left ventricular diastolic diameter Left ventricular diameter measured at end ventricular diastole (in centimeters). Indicate whether by
M-mode or two-dimensional imaging.
Left ventricular systolic function Subjective assessment as:
• Normal
• Mildly decreased
• Mild to moderately decreased
• Moderately decreased
• Moderately to severely decreased
• Severely decreased
Ejection fraction Number measured (specify technique) or estimated. Give midpoint if range given. Listed as a percentage.
Left ventricular diastolic function Categories include:
• Normal
• Impaired relaxation (Grade I)
• Pseudonormal (Grade II)
• Restrictive, reversible (Grade III)
• Restrictive, irreversible (Grade IV)
• Not obtained
Left ventricular wall thickness Left ventricular end-diastolic thickness of septal and posterior walls as measured in the parasternal
long-axis view (in centimeters). Indicate whether by M-mode or two-dimensional imaging.
Thrombus with location • Left atrial appendage
• Left atrium
• Right atrium
• Left ventricle
• Right ventricle
Indicate all that apply.
Spontaneous echo contrast with location • Left atrial appendage
• Left atrium
• Right atrium
• Left ventricle
• Right ventricle
Indicate all that apply.
Mitral valve morphology Predominant assessment as:
• Normal
• Rheumatic
• Myxomatous
• Prolapsed
• Flail
• Prosthetic
• Other abnormal, specify
Mitral stenosis Mitral valve area estimated from the pressure half-time of the left ventricular inflow (220/pressure
half-time)
Mitral regurgitation • None
• Mild
• Mild to moderate
• Moderate
• Moderate to severe
• Severe
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Other valvular disease List other valvular disease and severity.
Aortic plaque • Small (less than 1 mm)
• Moderate (1 to 4 mm)
• Large (greater than 4 mm)
• Mobile
Brain Imaging
Head CT or MRI Indicate evidence of ischemic or hemorrhagic events on head CT or MRI. Also indicate other major
abnormalities.
Quality of Life (See “General Considerations of the AF Clinical Data Standards” for a brief consideration of quality-of-life issues.)
Self-reported health status Ask patient: “In general, compared to other people your age, would you say your health is  ”:
• Excellent
• Very good
• Good
• Fair
• Poor
Symptoms with prior episodes of AF For each of (a) usual episode and (b) worst episode, symptoms as described by the patient as:
• Minimal or no symptoms
• Disabling
Summary Assessment
Heart failure status: New York Heart
Association (NYHA) classification
NYHA class as reported by a physician (definitions adopted from NYHA without revision):
• Class I: Patients with cardiac disease but without resulting limitations of physical activity. Ordinary
physical activity does not cause undue fatigue, palpitation, or dyspnea.
• Class II: Patients with cardiac disease resulting in slight limitation of physical activity. They are
comfortable at rest. Ordinary physical activity results in fatigue, palpitation, or dyspnea.
• Class III: Patients with cardiac disease resulting in marked limitation of physical activity. They are
comfortable at rest. Less than ordinary activity causes fatigue, palpitation, or dyspnea.
• Class IV: Patients with cardiac disease resulting in inability to perform any physical activity without
discomfort. Symptoms are present even at rest or on minimal exertion. If any physical activity is
undertaken, shortness of breath is increased.
Angina status Category of patient’s angina type if present (choose one):
• Atypical chest pain: Pain, pressure, or discomfort in the chest, neck, or arms not clearly exertional
or not otherwise consistent with pain or discomfort of myocardial ischemic origin.
• Stable angina: Angina without a change in frequency or pattern for the 6 weeks before this
procedure. Angina is controlled by rest and/or sublingual/oral/transdermal medications.
• Unstable angina (one of the following criteria is necessary):
Angina that occurred at rest and was prolonged, usually lasting more than 20 minutes
New-onset angina of at least Canadian Cardiovascular Society (CCS) class III severity
Recent acceleration of angina reflected by an increase in severity of at least 1 CCS class to at
least CCS class III
• Myocardial Infarction: For a complete definition, please refer to “Myocardial Infarction (MI)” in the
“Other Events” section.
Angina class: Canadian Cardiovascular
Society (CCS) classification
Grading of patient’s angina by class (CCS classification system) (21,22):
• Class I: Ordinary physical activity, such as walking or climbing stairs, does not cause angina. Angina
occurs with strenuous, rapid, or prolonged exertion at work or recreation.
• Class II: Slight limitation of ordinary activity. Angina occurs on walking or climbing stairs rapidly,
walking uphill, walking or climbing stairs after meals, or in cold, in wind, or under emotional stress,
or only during the few hours after awakening. Angina occurs on walking more than 2 blocks on the
level and climbing more than 1 flight of ordinary stairs at a normal pace and in normal condition.
• Class III: Marked limitations of ordinary physical activity. Angina occurs on walking 1 to 2 blocks on
the level and climbing 1 flight of stairs in normal conditions and at a normal pace.
• Class IV: Inability to perform any physical activity without discomfort—anginal symptoms may be
present at rest.
Cardioversion
Site Indicate all that apply.
• Transthoracic (single defibrillator)
• Transthoracic (dual defibrillators)
• Intracardiac/intravascular
• Epicardial
Waveform Categories include:
• Monophasic, all types
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• Rectilinear biphasic
• Truncated exponential biphasic
• Other, specify
Number of shocks delivered Indicate the number of shocks delivered during current session.
Maximal energy used Indicate maximal energy used in current session.
Medication for cardioversion attempt List generic name for medication used to attempt cardioversion for a patient from AF to normal sinus
rhythm. Indicate route of administration (intravenous or oral) and total daily dose and units. (Include total
dose until cardioversion or accepted failure.)
Success of cardioversion attempt Absence of AF or atrial flutter for at least 10 seconds after shock delivery or at any time after
antiarrhythmic drug administration. For pharmacological cardioversion, time frame for assessment will
depend on medication and route of administration (e.g., success for intravenous ibutilide may be within 1
hour from the end of infusion, whereas success for oral amiodarone may be within several days).
Pattern of recurrence After successful conversion:
• Immediate recurrence of AF (returns in less than 2 minutes)
• Subacute recurrence of AF (returns between 2 minutes and 14 days)
• Late recurrence of AF (returns after 14 days)
Complications of conversion Include all complications occurring from the initiation of cardioversion attempt to 28 days after
cardioversion. Specify complication and categorize into:
• Anesthesia related
• Thromboembolic
• Arrhythmic
• Other
Nonpharmacological Therapy
Supraventricular ablation Indications (may have more than one):
• Supraventricular tachycardia (e.g., AV node re-entry tachycardia, AV re-entry tachycardia, atrial
tachycardia)
• Atrial fibrillation
• Atrial flutter
• Other, specify
For AF/atrial flutter, indicate approach taken:
• Focal (specify site)
• Cavotricuspid isthmus
• Other linear sites, specify
• Atrioventricular node ablation plus permanent pacemaker
Indicate energy source:
• Radiofrequency
• Cryoablation
• Ultrasound
• Laser
• Other, specify
Pacemaker insertion Specify type:
• Single chamber (atrial)
• Single chamber (ventricular)
• Dual chamber (both atrial and ventricular, but not biventricular)
• Biventricular of any type
Specify indication: (all that apply)
• Sinus node dysfunction
• AV block
• Intraventricular (IV) block
• Congestive heart failure
• Atrial fibrillation with bradycardia
• Atrial fibrillation without bradycardia
Specify whether capable of:
• Pacing for prevention of atrial arrhythmias
• Burst/antitachycardia pacing for tachycardia termination
Intracardiac defibrillator insertion Specify type:
• Single chamber
• Dual chamber
• Biventricular
Specify indication:
• Atrial fibrillation
• Secondary prevention of cardiac arrest
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• Primary prevention of cardiac arrest. High risk for ventricular tachycardia (e.g., hypertrophic
cardiomyopathy, Brugada syndrome, long-QT syndrome)
• Syncope with inducible ventricular tachycardia
Specify whether capability exists:
• Burst pacing
• Antitachycardia pacing
• Cardioversion
Surgery/type • Maze:
Approach: epicardial/endocardial
Energy: radiofrequency ablation, cryoablation, laser, other
• Other, specify
Complications of nonpharmacological
therapy
Include all complications occurring from the initiation of nonpharmacological therapy to 28 days after
nonpharmacological therapy. Specify complication and categorize into:
• Anesthesia related
• Thromboembolic
• Arrhythmic
• Procedural
• Other
Thromboembolic Events
Ischemic stroke Documented stroke or cerebrovascular accident consisting of acute loss of neurological function caused
by an ischemic event with residual symptoms at least 24 hours after onset. The date of the most recent
stroke should be noted. List most likely etiology:
• Larger-artery disease (e.g., carotid)
• Small-artery disease (lacunar)
• Embolism
• Not specified
Indicate whether confirmed by CT, MRI scan, or cerebral angiography.
Severity of stroke Assessed at approximately 3 months after event. Categories include:
• Complete/near-complete recovery (able to return to prestroke level of function)
• Mild to moderate deficit (deficits present, but patient can perform activities of daily living, such as
dressing and feeding, with no or little assistance).
• Severe deficit (required assistance to complete activities of daily living)
Transient ischemic attack Acute loss of neurological function caused by an ischemic event with resolution of symptoms by 24 hours
after onset.
Non-central nervous system arterial embolic
event
Abrupt vascular insufficiency associated with clinical and radiological evidence of arterial occlusion in a
vascular bed other than the cerebrovascular system in the absence of other likely mechanisms (e.g.,
atherosclerosis). In the presence of peripheral arterial disease, diagnosis of embolism requires
angiographic demonstration of abrupt arterial occlusion.
Hemorrhagic Events
Intracranial hemorrhage Bleeding into or around the brain:
• Hemorrhagic conversion of a primary ischemic stroke
• Subarachnoid hemorrhage
• Intracerebral hemorrhage
• Other (including subdural and epidural hematomas)
• Unknown
Indicate whether documented by CT or MRI.
Other hemorrhage Bleeding is defined as either major or minor according to the following criteria:
• Major: Leading to transfusion of at least 2 units of whole blood or erythrocytes, requiring
hospitalization or surgery, resulting in permanent disability, or involving a critical anatomic site
(retroperitoneal, pericardial, intraspinal, intracranial, atraumatic intra-articular, or intra-ocular
bleeding associated with abrupt deterioration of visual acuity).
• Clinically overt (but not major)
• Occult (e.g., asymptomatic guaiac-positive stool)
Include amount of hemoglobin drop and the time interval if data available.
Transfusion Transfusion of either whole blood or packed red blood cells due to a hemorrhagic event. Note the number
of units transfused. Specify type (e.g., whole blood, packed erythrocytes, other blood products) and
quantity (units or milliliters).
Procedural intervention to control bleeding Indicate type of procedural intervention (e.g., surgical or catheter-based) performed to control an episode
of bleeding.
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Adverse Drug or Device Event
Adverse drug or device event An adverse event is any untoward medical occurrence in a patient or clinical investigation subject
administered a pharmaceutical product or a medical device and which does not have to have a causal
relationship with this treatment. Information regarding an adverse event should include:
• Generic name of drug or device associated with the event
• Dose, if applicable
• Cardiac: Subcategories of cardiac reactions include:
Congestive heart failure
Classic torsade de pointes
Other sustained ventricular tachycardia or fibrillation
Supraventricular tachycardia
Mobitz type II or third-degree AV node block
Mobitz type I or first-degree AV heart block
Sinus bradycardia
Other cardiac. Briefly specify
• Noncardiac, specify
• Severity. A serious adverse event is defined as one that satisfies any of the following criteria:
Results in death
Is life-threatening (NOTE: The term “life-threatening” in the definition of “serious” refers to an
event in which the patient was at risk of death at the time of the event; it does not refer to an
event that hypothetically might have caused death if it were more severe.)
Requires inpatient hospitalization or prolongation of existing hospitalization
Results in persistent or significant disability or incapacity
Is a congenital abnormality or birth defect
• Nonserious Event
• Causality: Relationship of adverse event to the drug as determined by the judgment of the
investigator:
Definite
Probable
Possible
• Action Taken:
Drug or device permanently stopped
Dose reduced or device changed
Drug or device temporarily stopped
Drug dosage or device not changed
Resource Utilization
Hospital admission Official admission to a hospital or other acute healthcare facility. Include dates of admission and
discharge.
Primary reason for admission Primary diagnosis of the event that prompted admission, as determined by the judgment of the
investigator, given as text description and latest ICD code (e.g., ICD-9 or ICD-10). May be the same as
principal discharge diagnosis.
Number of days in intensive care Number of days in intensive care
Principal discharge diagnosis Principal discharge diagnosis listed in official record (e.g., used for reimbursement), given as text
description and latest ICD code (e.g., ICD-9 or ICD-10)
Emergency department visit Include visits not resulting in hospitalization.
Procedures performed In addition to the procedure information obtained elsewhere in the data set (e.g., ECG, ablation,
cardioversion, pacemaker/implantable cardioverter-defibrillator implant, echocardiography), other important
procedures to document utilization include:
• Chest X-ray
• Exercise test (list imaging techniques if performed)
• Holter monitor
• Electrophysiology study
• Angiography
• Percutaneous intervention
• Bypass surgery
• Valve repair/replacement
Specialty of principal provider Indicate specialty of any provider substantially involved with decision making for encounter. Indicate all
that apply:
• Electrophysiologist
• Cardiologist (nonelectrophysiologist)
• Internist (noncardiologist)
• Family physician
• Other, specify
492 McNamara et al. JACC Vol. 44, No. 2, 2004
ACC/AHA Clinical Data Standards: Atrial Fibrillation July 21, 2004:475–95
TABLE 2. Continued
ELEMENT DEFINITION
Other Events
Myocardial infarction Either one of the following criteria satisfies the diagnosis for an acute, evolving, or recent MI:
• Typical rise and gradual fall (troponin) or more rapid rise and fall (creatine kinase–MB) of
biochemical markers of myocardial necrosis with at least 1 of the following:
Ischemic symptoms
Development of pathological Q waves on the ECG
ECG changes indicative of ischemia (ST-segment elevation or depression)
Coronary artery intervention (e.g., coronary angioplasty) preceding enzyme rise
Or
• Pathological findings of an acute MI
In addition, indicate whether the MI is:
• ST-elevation MI
• Non–ST-elevation MI
• Based on presence of complete left bundle-branch block or uncertain
Death Death includes all deaths regardless of etiology. Specify location
• Hospital
• Other institution
• Community (includes home)
Cause of death Primary cause of death as determined by investigator:
• Cardiovascular death indicates cause of death was sudden cardiac death, MI, unstable angina, or
other coronary artery disease; vascular death (e.g., stroke, arterial embolism, pulmonary embolism,
ruptured aortic aneurysm, or dissection); congestive heart failure; or cardiac arrhythmia. Consider
further specifications, such as:
Myocardial infarction
Ischemic stroke
Primary arrhythmic death (without MI)
Progressive heart failure
Intracranial hemorrhage
Non–intracranial hemorrhage-related death
Unexplained sudden death
Other cardiovascular, specify
• Noncardiovascular death, specify
• Unknown/unable to categorize
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Appendix A
External Peer Reviewers
TABLE 3. External Peer Reviewers: ACC/AHA Atrial Fibrillation Clinical
Data Standards*
Reviewer Name† Reviewer Category and Affiliation
Official Reviewers
W. Barton Campbell, MD, FACC ACC Board of Governors
Valentin Fuster, MD, PhD, FACC ACC/AHA Task Force on Practice Guidelines
Bruce Lindsay, MD, FACC ACC Board of Trustees
Martha Radford, MD, FACC, FAHA ACC/AHA Task Force on Data Standards Lead Reviewer
David Sherman, MD, FAHA AHA Reviewer, Neurology
Albert Waldo, MD, FACC, FAHA AHA Reviewer
Content Reviewers
A. John Camm, MD, FACC Individual
Jamie Conti, MD, FACC Individual
James Emery, MD, FACC ACC Board of Governors Secondary Reviewer
Linda Gillam, MD, FACC Individual
David Goff, MD Individual
Robert Hong, MD, FACC ACC Board of Governors Secondary Reviewer
Ira Nash, MD, FACC Individual
Richard Page, MD, FACC Individual
Edward Pritchett, MD, FACC Individual
Denis Roy, MD, FACC Individual
*Participation in the peer review process does not imply endorsement of the document.
†Names are listed in alphabetical order within each category of review.
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